Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluatin

EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE)

Related Keywords

California , United States , San Francisco , Robert Flamm , Kostenloser Wertpapierhandel , Lisa Danzig , Daniel Dornbusch , John Fraunces , Rachelm Presti , Excision Biotherapeutics Inc , Loreda Holdings , Burns Mcclellan Inc , Temple University , Chief Executive Officer , Chief Medical Officer , Associate Professor , Washington University School , Principal Investigator , Greatpoint Ventures , Norwest Venture Partners , Adjuvant Capital , Cota Capital , Celesta Capital , Indusage Partners , Olive Tree , Anzu Partners , Silverridge Venture Partners , Oakhouse Ventures , Excision , Iotherapeutics , Nitiates , Hase , Trial , Valuating , Potential , Cure ,